AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33097947
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2000 mg/d DHA + 400 mg/d EPA)
Trial: 33097947
Drug: Curcumin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (160 mg/d)
Trial: 33737025
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg twice daily for extended thromboprophylaxis (ETP) after radical cystectomy
Trial: 33114457
Drug: Family-based mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based mental health program, eight sessions, details on dosage and duration not specified.
Trial: 33324593
Drug: Isoniazid exposure
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid exposure during tuberculosis preventive treatment (IPT)
Trial: 33324593
Drug: Multi-B vitamin
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-B vitamin therapy (containing 300 mg nicotinamide daily) and isoniazid cessation
Trial: 33324593
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of niacin metabolites (1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide) in urine
Trial: 34145993
Drug: Levosimendan (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.2 μg/kg/min for 24 hours)
Trial: 34406254
Drug: Pulsed Electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Electromagnetic Field (PEMF) therapy applied at 50 Hz, 25 G intensity, 20 min/session
Trial: 32792250
Drug: IIV by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV by MNP administered by healthcare worker (HCW)
Trial: 32792250
Drug: IIV by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV by MNP self‐administered by study participants
Trial: 32792250
Drug: IIV by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV by intramuscular (IM) injection administered by HCW
Trial: 32792250
Drug: Placebo by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by MNP administered by HCW
Trial: 33870760
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin adhesive (TSA)
Trial: 34292180
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg preoperatively + 40 mg/day postoperatively (80/40-mg group)
Trial: 34292180
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day postoperatively (20-mg group)
Trial: 34292180
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day postoperatively (40-mg group)
Trial: 32415684
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg single dose
Trial: 32415684
Drug: Selexipag 200
RxNorm normalized name: SELEXIPAG 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag 200 μg twice daily
Trial: 34313812
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 10 mg weekly
Trial: 35355656
Drug: Norepinephrine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (6 μg/mL) infused at 60 mL/h
Trial: 35355656
Drug: Phenylephrine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (75 μg/mL) infused at 60 mL/h
Trial: 35254839
Drug: IV nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg/70 kg)
Trial: 35254839
Drug: IV nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV nicotine (0.1 mg)
Trial: 32275361
Drug: Tiaoshen acupuncture
RxNorm normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaoshen acupuncture (acupuncture for regulating the spirit) applied in the observation group, including additional acupoints Baihui (GV 20), Shenting (GV 24), and Benshen (GB 13). Treatment given once a day, 6 times a week, for 3 weeks.
Trial: 32275361
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture at lower limbs' acupoints (Zusanli (ST 36), Yanglingquan (GB 34), and Xuanzhong (GB 39)) applied in the control group. Treatment given once a day, 6 times a week, for 3 weeks.
Trial: 33951339
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg CBD twice daily with 200 mg caffeine on day 26
Trial: 33951339
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 200 mg caffeine on day 1
Trial: 35633196
Drug: Acetaminophen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (20 mg/kg PO)
Trial: 35633196
Drug: Acetaminophen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (30 mg/kg PO)
Trial: 35633196
Drug: Phenylbutazone (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (2.2 mg/kg PO)
Trial: 35633196
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (C)
Trial: 32907603
Drug: Multicomponent implementation
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent implementation strategy including training and point-of-service tools (e.g., desktop chart with prompts for offering brief counseling)
Trial: 32771996
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticagrelor for 3 months
Trial: 32771996
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel for 3 months
Trial: 32771996
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without HPR continued on aspirin and clopidogrel
Trial: 34797205
Drug: Real GSM
RxNorm normalized name: carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real GSM 900 MHz mobile phone exposure (pulse modulated at 217 Hz, mean power of 250 mW and 2 W peak, with a maximum specific absorption rate of 0.70 W/kg on 1 g tissue)
Trial: 35843242
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with salvage chemotherapy followed by autologous stem cell transplantation
Trial: 36286254
Drug: Haloperidol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2.5 mg 3 times daily plus 2.5 mg as needed, max 20 mg daily)
Trial: 35815359
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICSs)
Trial: 34599031
Drug: Seviprotimut-L 40
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seviprotimut-L 40 mcg
Trial: 37942666
Drug: Titanium-zirconium (TiZr)
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium-zirconium (TiZr) implants
Trial: 38335499
Drug: Prednisone 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 0.75 mg/kg/d
Trial: 35786344
Drug: Nano-curcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (80 mg/day)
Trial: 34635802
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg/day
Trial: 32980280
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication (paracetamol, NSAID, opioids, neuropathic pain medication)
Trial: 32980280
Drug: Neuropathic pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropathic pain medication
Trial: 33526485
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate (2.4 mg/kg)
Trial: 32293286
Drug: Inverse Probability
RxNorm normalized name: Inversedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse Probability of Treatment Weighting (IPTW)
Trial: 34813414
Drug: Prostacyclin 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin 1 ng/kg/min infusion for 72 hours
Trial: 32035624
Drug: Preflushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preflushing with saline at high speed (10 ml/s) before connecting to the catheter
Trial: 32035624
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection procedure (control group)
Trial: 34816795
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral amoxicillin (dose-by-age) given three times daily for 7 days
Trial: 34816795
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral amoxicillin (dose-by-age) given three times daily for 7 days
Trial: 34816795
Drug: Immediate topical
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate topical ciprofloxacin (0.3%) solution, four drops given three times daily for 7 days
Trial: 34192431
Drug: Daratumumab group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab group (subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles)
Trial: 36143902
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with nitinol stents (NS)
Trial: 33225990
Drug: Prone positioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prone positioning therapy throughout the day as long as possible, with breaks according to tolerance.
Trial: 33225990
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group allowed prone positioning as a rescue therapy.
Trial: 34001215
Drug: Camostat mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesylate (200 mg per capsule, one capsule taken each in the morning, afternoon, and evening on days 1-7)
Trial: 34001215
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical in appearance to camostat mesylate capsules, one capsule taken each morning, afternoon, and evening on days 1-7)
Trial: 34740607
Drug: Baked milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked milk oral immunotherapy (BMOIT)
Trial: 34642494
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg
Trial: 34642494
Drug: Bepirovirsen 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 150 mg
Trial: 34642494
Drug: Stable NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable NA therapy with Bepirovirsen
Trial: 36867504
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg apixaban
Trial: 35429485
Drug: Once-daily risdiplam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily risdiplam
Trial: 32127848
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg intravenously
Trial: 32127848
Drug: Fentanyl 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.0 µg/kg intravenously
Trial: 35648305
Drug: Qizi Yusi
RxNorm normalized name: Yusimry
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Qizi Yusi Pill (QYP)
Trial: 32207010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cooking fuels
Trial: 33001422
Drug: ACEI (Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (Angiotensin Converting Enzyme Inhibitor)
Trial: 33001422
Drug: ARB (Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (Angiotensin II Type I Receptor Blocker)
Trial: 32660143
Drug: Iprodione treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iprodione treatment on mutant M0
Trial: 32660143
Drug: Iprodione treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iprodione treatment on mutant M1
Trial: 32660143
Drug: Iprodione treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iprodione treatment on wild type W0
Trial: 34305036
Drug: Acidulated phosphate
RxNorm normalized name: Acidulated Phosphate Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidulated phosphate fluoride gel (APF)
Trial: 34305036
Drug: Neutral fluoride
RxNorm normalized name: SODIUM FLUORIDE 0.9 mg in 1 g DENTAL AEROSOL, FOAM [KOLORZ NEUTRAL FLUORIDE FOAM TRIPLE MINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral fluoride gel (NGel)
Trial: 34305036
Drug: Without fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without fluoride treatment (control)
Trial: 39145520
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron supplementation
Trial: 36078489
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training group (CTG)
Trial: 34587808
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional 24-hour postoperative oral regime of four 1 g doses
Trial: 34587808
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative intravenous dose of 1 g TXA
Trial: 34587808
Drug: No TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TXA administered
Trial: 34800364
Drug: NVX-CoV2373 plus
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 plus the influenza vaccine
Trial: 34800364
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus the influenza vaccine
Trial: 33514449
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg)
Trial: 32335844
Drug: BIIB059 (anti-BDCA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB059 (anti-BDCA2 monoclonal antibody) administered intravenously and subcutaneously, dosage not specified.
Trial: 34251873
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2) and docetaxel (85 mg/m2) followed by durvalumab (750 mg)
Trial: 34251873
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin and docetaxel
Trial: 34251873
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by durvalumab
Trial: 33129910
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel)
Trial: 33793460
Drug: mRNA BNT162b2
RxNorm normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (full immunization, ≥14 days after second dose)
Trial: 33793460
Drug: mRNA BNT162b2
RxNorm normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (partial immunization, ≥14 days after first dose and before second dose)
Trial: 32876987
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (30 g in 200 mL warm water at fasting time for 4 weeks)
Trial: 32876987
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g in 200 mL warm water at fasting time for 4 weeks)
Trial: 36079822
Drug: Nutritional supplements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements, diet education, and standard care
Trial: 33354755
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention involving medication therapy problem identification and recommendations
Trial: 33354755
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy problems related to indication, effectiveness, and safety
Trial: 36003379
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agents (HMAs)
Trial: 32573121
Drug: Drainage–injection–pneumoretinopexy (DIP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drainage–injection–pneumoretinopexy (DIP)
Trial: 34050594
Drug: High-dose losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose losartan
Trial: 34050594
Drug: Low-dose losartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose losartan
Trial: 33966293
Drug: Cumulative melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative melphalan exposure among cases (median 988 mg; IQR 644-1640)
Trial: 33966293
Drug: Cumulative melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative melphalan exposure among controls (median 578 mg; IQR 360-967)
Trial: 32248243
Drug: GAD-alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (20 μg, administered twice or three times)
Trial: 33735594
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (Ferinject) 1,000 mg or 15 mg/kg if weight <66.7 kg
Trial: 33735594
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran (Cosmofer) 20 mg iron/kg body weight
Trial: 35873404
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of ashwagandha root extract twice daily
Trial: 32583313
Drug: Allisartan 240
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allisartan 240 mg/day and lifestyle modification
Trial: 33589590
Drug: Venlafaxine extended-release
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended-release for 12 weeks
Trial: 33000160
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g oral l-histidine daily for 8 weeks
Trial: 33000160
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g l-histidine daily for 12 weeks
Trial: 33000160
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g l-histidine daily
Trial: 35389028
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream alone (control group)
Trial: 35389028
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream + microneedling
Trial: 35389028
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream + tranexamic acid (TA 250 mg twice daily)
Trial: 35389028
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream + microneedling + tranexamic acid
Trial: 36092537
Drug: Low-volume split-dose
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume split-dose regimen two (1.5L PEG after dinner, 0.75L PEG 4 hours before colonoscopy)
Trial: 36092537
Drug: Low-volume split-dose
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume split-dose regimen one (0.75L PEG after dinner, 1.5L PEG 4 hours before colonoscopy)
Trial: 32894785
Drug: Siltuximab (anti-IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (anti-IL-6 therapy)
Trial: 36396412
Drug: Instructing parents
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructing parents to read daily